Drugs that contain Brimonidine Tartrate; Timolol Maleate
1. List of Combigan drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7642258 | ALLERGAN | Combination of brimonidine and timolol for topical ophthalmic use |
Apr, 2022
(9 months ago) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7320976 | ALLERGAN | Combination of brimonidine and timolol for topical ophthalmic use |
Apr, 2022
(9 months ago) | |
| US8133890 | ALLERGAN | Combination of brimonidine and timolol for topical ophthalmic use |
Apr, 2022
(9 months ago) | |
| US9770453 | ALLERGAN | Combination of brimonidine and timolol for topical ophthalmic use |
Apr, 2022
(9 months ago) | |
| US9907801 | ALLERGAN | Combination of brimonidine and timolol for topical ophthalmic use |
Apr, 2022
(9 months ago) | |
| US8354409 | ALLERGAN | Combination of brimonidine and timolol for topical ophthalmic use |
Apr, 2022
(9 months ago) | |
| US8748425 | ALLERGAN | Combination of brimonidine and timolol for topical ophthalmic use |
Apr, 2022
(9 months ago) | |
| US9907802 | ALLERGAN | Combination of brimonidine and timolol for topical ophthalmic use |
Apr, 2022
(9 months ago) | |
| US9474751 | ALLERGAN | Combination of brimonidine and timolol for topical ophthalmic use |
Apr, 2022
(9 months ago) | |
| US7030149 | ALLERGAN | Combination of brimonidine timolol for topical ophthalmic use |
Apr, 2022
(9 months ago) | |
| US7323463 | ALLERGAN | Combination of brimonidine and timolol for topical ophthalmic use |
Jan, 2023
(11 days ago) | |
Market Authorisation Date: 30 October, 2007
Treatment: Reduction of elevated intraocular pressure (iop) in patients with glaucoma or ocular hypertension who require adjunctive or replacement therapy due to inadequately controlled iop. dose is one drop of combigan in the affected eye twice daily; Reduction of elevated intraocular pressure in patients with glaucoma or ocular hypertension; Reduction of elevated intraocular pressure (iop) in patients with glaucoma or ocular hypertension, with comparable efficacy, and a reduction in specified adverse events, compared to brimonidine 0.2% tid; Reduction of elevated intraocular pressure (iop) in patients with glaucoma or ocular hypertension, with a reduction in specified adverse events, compared to brimonidine 0.2% tid; Reduction of intraocular pressure in patients with elevated intraocular pressure or glaucoma; Reduction of elevated intraocular pressure; Reduction of elevated intraocular pressure (iop) in patients with glaucoma or ocular hypertension, with comparable efficacy to brimonidine 0.2% tid; Reduction of elevated intraocular pressure in patients with glaucoma or ocular hypertension who require adjunctive or replacement therapy due to inadequately controlled iop
Dosage: SOLUTION/DROPS;OPHTHALMIC
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic